Kings College Hospital

London, Greater London SE5 9RS

4 studies enrolling now · 21 studies all time

What they study most

Acute Lung Injury, Acute Respiratory Distress Syndrome, Brain Edema, Branch Retinal Vein Occlusion, COVID-19 Severe Pneumonia, Central Retinal Vein Occlusion, Chronic Graft Versus Host Disease, Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Chronic Myeloid Leukemia (for Part B and C), Colitis, Ulcerative, Diabetic Macular Edema, Healthy (For Part A)

Studies at this site

• A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines — Recruiting now
• A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) — Recruiting now
• A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC) — Recruiting now
• A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis — Recruiting now
• ABTECT - Maintenance — Running, not enrolling
• Study to Assess the Efficacy, Safety, and Tolerability of NOC-110 in Adults With Refractory or Unexplained Chronic Cough — Running, not enrolling
• A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products — Running, not enrolling
• Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML Resistant/Intolerant to ≥3 Prior CML Therapies — Stopped early
• A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL) — Running, not enrolling
• ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1 — Completed
• Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction — Stopped early
• Long-Term Tolerability and Safety of HYQVIA/HyQvia in CIDP — Completed
• Evaluate F901318 (Olorofim) Treatment of Invasive Fungal Infections in Participants Lacking Treatment Options — Completed
• A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab Administration — Completed
• A Study of HyQvia and Gammagard Liquid (Kiovig) in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) — Completed
• A Study of Lasmiditan (LY573144) Over Four Migraine Attacks — Completed
• Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia — Stopped early
• An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine — Completed
• A Study of Galcanezumab (LY2951742) in Adults With Treatment-Resistant Migraine — Completed
• Extracorporeal Photopheresis (ECP) With Methoxsalen for Chronic Graft Versus Host Disease (cGVHD) — Completed
• Three-year Follow-up Study of Subjects Who Participated in a Previous Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) Chronic Hepatitis C Clinical Trial — Completed